
    
      NDMM patients induction therapy with 4 cycles PCD/PAD regimen, achieve â‰¥PR, eligible for SCT,
      were randomly divided into two arms. One arm receive microtransplantation, and the other
      accept auto-SCT. Comparison of the efficacy and safety of two arms, 2-year PFS and OS were
      also been observed. Clear the above program related hematopoietic recovery, remission rate,
      infection and recurrence rate, survival rate and the formation of micro inlay, minimal
      residual disease and GVHD, etc. To identify the role of microtransplantation in the treatment
      of multiple myeloma.
    
  